-
1 Comment
Akari Therapeutics, Plc is currently in a long term downtrend where the price is trading 24.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Akari Therapeutics, Plc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 156.2% to $1M since the same quarter in the previous year.
Finally, its free cash flow grew by 85.7% to $-704K since the same quarter in the previous year.
Based on the above factors, Akari Therapeutics, Plc gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | US00972G2075 |
Market Cap | 41M |
---|---|
PE Ratio | 0.0 |
Target Price | 80 |
Beta | 0.25 |
Dividend Yield | None |
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) and a novel discovery engine. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. In addition, its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. Further, the company develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AKTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025